In animal studies, the vaccine was found to elicit a strong immune response in multiple animal species like mice, rats, guinea pigs, and rabbits. The antibodies produced by the vaccine were able to completely neutralize the wild type virus in virus neutralization assay, indicating the protective potential of the vaccine candidate, Cadila Healthcare
No safety concerns were observed for the vaccine candidate in repeat dose toxicology studies by both intramuscular and intradermal routes of administration. In rabbits, up to three times the intended human dose was found to be safe, well tolerated and immunogenic, it said.
The company intends to now rapidly ramp up the production capacities of ZyCoV-D at multiple sites and facilities to cater to Indian and global demand.
At 09:20 am, Cadila Healthcare
had erased its early morning surge and was trading 1.7 per cent higher at Rs 369.55 on the BSE, as compared to 0.35 per cent rise in the S&P BSE Sensex. The stock was trading close to its 52-week high of Rs 383.65, touched on June 15, 2020. A combined 1.98 million equity shares have changed hands on the counter on the NSE and BSE, so far.